Dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with symptomatic chronic heart failure with left ventricular ejection fraction > 40%
- Without type 2 diabetes mellitus and without chronic kidney disease: hint of non-quantifiable added benefit
- With/without type 2 diabetes mellitus and with chronic kidney disease: hint of non-quantifiable added benefit
- With type 2 diabetes mellitus and without chronic kidney disease: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.
Project details
- Project no.
- A23-11
- Commission
- Commission awarded on 27.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Addendum
Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11
Status: Commission completed